The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
The PI3K/AKT Pathway and Renal Cell Carcinoma
Open accessAbstract
The phosphatidylinositol 3 kinase (PI3K)/AKT pathway is genetically targeted in more pathway components and in more tumor types than any other growth factor signaling pathway, and thus is frequently activated as a cancer driver. More importantly, the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades, providing many potential targets for cancer therapy. Renal cell carcinoma (RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies. The PI3K/AKT pathway is modestly mutated but highly activated in RCC, representing a promising drug target. Indeed, PI3K pathway inhibitors of the rapalog family are approved for use in RCC. Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC, reiterating the critical role of the PI3K/AKT pathway in this cancer. In this review, we summarizes the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data, as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Furthermore, high intratumor genomic heterogeneity has been detected in ccRCC (Gerlinger et al., 2012; Gerlinger et al., 2014); therefore, current mutation and CNA data represent only a small fraction of the full spectrum of genetic alterations in a given tumor.”
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · cited 4×
“At the layer downstream of AKT, mutations in TSC1/TSC2 have been identified but are relatively rare (Lawrence et al., 2014).”
InfluentialAlessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationTargeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Self-citationThe functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Mesopelagic fish biomass and trophic efficiency of the open ocean
Irigoien, X., Klevjer, J., Røstad, A., Martínez, U., Boyra, G., Acuña, J. L., Bode, A., Echevarrı́a, F., González-Gordillo, J. L., Hernández‐León, S., et al. (2014) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · Cited by 1,813
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Hornbeck, P. V., Kornhauser, J. M., Tkachev, S., Zhang, B., Skrzypek, E., Murray, B., Latham, V., & Sullivan, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1122 · Cited by 1,646
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Akt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., Fisher, R., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,208
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Self-citationExome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Self-citationRole of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Auger, K. R., Serunian, L. A., Soltoff, S. P., Libby, P., & Cantley, L. C. (1989) · Cell · doi:10.1016/0092-8674(89)90182-7 · Cited by 908
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Davis, C. F., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., Buhay, C., Kang, H., Kim, S. C., Fahey, C. C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.014 · Cited by 842
Advances in protein kinase B signalling: AKTion on multiple fronts
Brazil, D. P., Yang, Z.-Z., & Hemmings, B. A. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.03.006 · Cited by 830
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Jonasch, E., Gao, J., & Rathmell, W. K. (2014) · BMJ · doi:10.1136/bmj.g4797 · Cited by 636
Self-citationEssential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., & Guan, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.119 · Cited by 610
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Akbani, R., Ng, P. K. S., Werner, H. M. J., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.-Y., Yoshihara, K., Li, J., et al. (2014) · Nature Communications · doi:10.1038/ncomms4887 · Cited by 607
Self-citationImproved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4921 · Cited by 588
Activation of phosphatidylinositol 3-kinase by insulin.
Ruderman, N. B., Kapeller, R., White, M. F., & Cantley, L. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1411 · Cited by 524
TCPA: a resource for cancer functional proteomics data
Li, J., Lu, Y., Akbani, R., Ju, Z., Roebuck, P. L., Liu, W., Yang, J.-Y., Broom, B. M., Verhaak, R. G. W., Kane, D. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2650 · Cited by 512
Self-citationRheb fills a GAP between TSC and TOR
Manning, B. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.003 · Cited by 483
Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke-Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 470
Self-citationTremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706517104 · Cited by 465
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
Grabiner, B. C., Nardi, V., Birsoy, K., Possemato, R., Shen, K., Sinha, S., Jordan, A., Beck, A. H., & Sabatini, D. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0929 · Cited by 450
PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival
Bozulic, L., Surucu, B., Hynx, D., & Hemmings, B. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.024 · Cited by 386
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR
Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., Cordon-Cardo, C., Celeste Simon, M., Rafii, S., & Pandolfi, P. P. (2006) · Nature · doi:10.1038/nature05029 · Cited by 378
Powell, D. J., Hajduch, E., Kular, G., & Hundal, H. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7794-7808.2003 · Cited by 370
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning
Cai, S.-L., Tee, A. R., Short, J. D., Bergeron, J. M., Kim, J., Shen, J., Guo, R., Johnson, C. L., Kiguchi, K., & Walker, C. L. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507119 · Cited by 359
Oh, W. J., Wu, C. ‐., Kim, S. J., Facchinetti, V., Julien, L. ‐., Finlan, M., Roux, P. P., Su, B., & Jacinto, E. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.271 · Cited by 333
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 301
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Jaiswal, B. S., Janakiraman, V., Kljavin, N. M., Chaudhuri, S., Stern, H. M., Wang, W., Kan, Z., Dbouk, H. A., Peters, B. A., Waring, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.016 · Cited by 289
A novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
Self-citationA New Mutational aktivation in the PI3K Pathway
Brugge, J., Hung, M.-C., & Mills, G. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.014 · Cited by 263
Self-citationThe switches.ELM Resource: A Compendium of Conditional Regulatory Interaction Interfaces
Van Roey, K., Dinkel, H., Weatheritt, R. J., Gibson, T. J., & Davey, N. E. (2013) · Science Signaling · doi:10.1126/scisignal.2003345 · Cited by 247
Liang, H., Cheung, L. W. T., Li, J., Ju, Z., Yu, S., Stemke-Hale, K., Dogruluk, T., Lu, Y., Liu, X., Gu, C., et al. (2012) · Genome Research · doi:10.1101/gr.137596.112 · Cited by 241
Self-citationHuang, D., Ding, Y., Li, Y., Luo, W.-M., Zhang, Z.-F., Snider, J., VandenBeldt, K., Qian, C.-N., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3722 · Cited by 240
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Roe, J.-S., Kim, H., Lee, S.-M., Kim, S.-T., Cho, E.-J., & Youn, H.-D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.006 · Cited by 237
A Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Frew, I. J., & Moch, H. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040306 · Cited by 220
Landmarks in the diagnosis and treatment of renal cell carcinoma
Bhatt, J. R., & Finelli, A. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.194 · Cited by 218
Ack1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation
Mahajan, K., Coppola, D., Challa, S., Fang, B., Chen, Y. A., Zhu, W., Lopez, A. S., Koomen, J., Engelman, R. W., Rivera, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009646 · Cited by 175
Dillon, R. L., Marcotte, R., Hennessy, B. T., Woodgett, J. R., Mills, G. B., & Muller, W. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4287 · Cited by 169
Self-citationState of the Science: An Update on Renal Cell Carcinoma
Jonasch, E., Futreal, P. A., Davis, I. J., Bailey, S. T., Kim, W. Y., Brugarolas, J., Giaccia, A. J., Kurban, G., Pause, A., Frydman, J., et al. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0117 · Cited by 162
Self-citationRechsteiner, M., von Teichman, A., Nowicka, A., Sulser, T., Schraml, P., & Moch, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0757 · Cited by 112
The AKT genes and their roles in various disorders
Cohen, M. M. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36101 · Cited by 110
Xu, X., Wu, J., Li, S., Hu, Z., Xu, X., Zhu, Y., Liang, Z. C., Wang, X., Lin, Y., Mao, Y., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-109 · Cited by 108
Lu, Z. H., Shvartsman, M. B., Lee, A. Y., Shao, J. M., Murray, M. M., Kladney, R. D., Fan, D., Krajewski, S., Chiang, G. G., Mills, G. B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3467 · Cited by 106
Self-citationINPP4B: the New Kid on the PI3K Block
Agoulnik, I. U., Hodgson, M. C., Bowden, W. A., & Ittmann, M. (2011) · Oncotarget · doi:10.18632/oncotarget.260 · Cited by 106
Cheung, L. W. T., Yu, S., Zhang, D., Li, J., Ng, P. K., Panupinthu, N., Mitra, S., Ju, Z., Yu, Q., Liang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.08.017 · Cited by 105
Self-citationRecent developments in the treatment of renal cell carcinoma
Dutcher, J. P. (2013) · Therapeutic Advances in Urology · doi:10.1177/1756287213505672 · Cited by 96
Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art
Randall, J. M., Millard, F. E., & Kurzrock, R. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9533-1 · Cited by 87
Figlin, R. A., Kaufmann, I., & Brechbiel, J. L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28023 · Cited by 77
Fisher, R. A., Horswell, S. D., Rowan, A., Salm, M. P., de Bruin, E. C., Gulati, S., McGranahan, N., Stares, M., Gerlinger, M., Varela, I., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0433-z · Cited by 77
Mao, M., Fang, X., Lu, Y., LaPushin, R., Bast, R. C., & Mills, G. B. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3520475 · Cited by 76
Self-citationSite-specific activation of AKT protects cells from death induced by glucose deprivation
Gao, M., Liang, J., Lu, Y., Guo, H., German, P., Bai, S., Jonasch, E., Yang, X., Mills, G. B., & Ding, Z. (2013) · Oncogene · doi:10.1038/onc.2013.2 · Cited by 66
Self-citationEndersby, R., Zhu, X., Hay, N., Ellison, D. W., & Baker, S. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3597 · Cited by 61
Rechsteiner, M., von Teichman, A., Nowicka, A., Sulser, T., Schraml, P., & Moch, H. (2011) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-48869 · Cited by 59
Lian, J.-H., Wang, W., Wang, J., Zhang, Y., & Li, Y. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.9.5017 · Cited by 53
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo
Lee, C. M., Hickey, M. M., Sanford, C. A., McGuire, C., Cowey, C. L., Simon, M. C., & Rathmell, W. K. (2009) · Oncogene · doi:10.1038/onc.2009.12 · Cited by 46
Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules
Guo, H., Gao, M., Lu, Y., Liang, J., Lorenzi, P. L., Bai, S., Hawke, D. H., Li, J., Dogruluk, T., Scott, K. L., et al. (2013) · Oncogene · doi:10.1038/onc.2013.301 · Cited by 46
Self-citationGirardi, C., James, P., Zanin, S., Pinna, L. A., & Ruzzene, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.04.020 · Cited by 36
Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein
Ding, Z., Germán, P., Bai, S., Reddy, A. S., Liu, X.-D., Sun, M., Zhou, L., Chen, X., Zhao, X., Wu, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3213 · Cited by 31
Self-citationPapillary Renal Cell Carcinoma: Current Progress and Future Directions
Twardowski, P. W., Mack, P. C., & Lara, P. N. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.11.013 · Cited by 24
Cho, D. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829d5cea · Cited by 14
Murph, M. M., Smith, D. L., Hennessy, B. T., Lu, Y., Joy, C., Coombes, K. R., & Mills, G. B. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_15 · Cited by 8
Self-citationShrewd AKT regulation to survive
Dawood, M., Mills, G. B., & Ding, Z. (2014) · Oncoscience · doi:10.18632/oncoscience.16 · Cited by 7
Self-citation
Cited by
The PI3K/AKT Pathway in Obesity and Type 2 Diabetes
Huang, X., Liu, G., Guo, J., & Su, Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27173 · Cited by 1,673
“Phosphoinositide 3-kinase (PI3K) was discovered in 1985 and identified as a previously unknown phosphoinositide kinase [7, 8].”
BackgroundTargeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
Sun, K., Luo, J., Guo, J., Yao, X., Jing, X., & Guo, F. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.02.027 · Cited by 660
Makhov, P., Joshi, S., Ghatalia, P., Kutikov, A., Uzzo, R. G., & Kolenko, V. M. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1299 · Cited by 521
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Metadata
- Authors
- Guo, H., German, P., Bai, S., Barnes, S., Guo, W., Qi, X., Lou, H., Liang, J., Jonasch, E., Mills, G. B., & Ding, Z.
- Venue
- Journal of Genetics and Genomics
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 42
- Issue
- 7
- Pages
- 343-353
- ISSN
- 1873-5533 (ISSN-L)
- 1673-8527
- OpenAlex
- W2029884231
- Cited by
- 369
- References
- 95
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.